降血脂藥與新生糖尿病之統合研究

Lipid-Lowering Therapy Agents and Risk of New-Onset Diabetes: Meta-analysis

蔡崇煌(Chung-Huang Tsai)；江韶岳(Shao-Yueh Chiang)；林正介(Cheng-Chieh Lin)；李孟智(Meng-Chih Lee)；蘇家龍(Jia-Lung Su)

膽固醇吸收抑制劑 ； 新生糖尿病 ； 降脂療法 ； 枯草溶菌素轉化酶9抑制劑 ； Cholesterol absorption inhibitor ； New-onset diabetes ； Lipid-lowering therapy ； PCSK9 inhibitor

醫學與健康期刊

8卷1期（2019 / 03 / 01）

25 - 38

繁體中文

目的：過去的斯達汀類（statins）藥物研究發現，其對新生糖尿病有不同的結果，在此除statins外，我們多加分析常用的降脂治療藥物和其發展成新生糖尿病間的關係。方法：以EndNote X8.2內之PubMed搜尋2018年3月前之降脂治療藥物藥物試驗。使用I^2檢測研究間的異質性，用隨機效應做統合分析，計算各類藥物新生糖尿病的勝算比（OR）。使用RevMan 5.3統計軟體計算OR及95%信賴區間，再以MS-Excel畫森林圖。結果：共引用10篇文獻做統合分析，其中8篇為期刊，另2為具公信力之網路資料，結果發現高劑量statins增加新生糖尿病33%最嚴重（OR 1.33, 1.15-1.54），整體之降脂治療藥物會增加新生糖尿病95%（OR 1.09, 1.03-1.15），排除高劑量statins、膽固醇吸收抑制劑（ezetimibe）及枯草溶菌素轉化酶9抑制劑（PCSK9i）後，statins不會增加新生糖尿病（OR 1.07,0.99-1.15），然再排除pitavastatin，OR 1.08（1.003-1.15）會增加新生糖尿病8%的風險。Ezetimibe OR 1.04（0.94-1.16），未達統計學上顯著差異。PCSK9i之FOURIER研究（evolocumab）之OR 1.05（0.94-1.18），alirocumab則為OR 0.92（0.42-2.01），皆無增加新生糖尿病，且此類藥物次群組分析為OR 1.05（0.94-1.16），亦未有顯著差異。結論：不同類型和劑量的降脂治療藥物之新生糖尿病亦不同，高劑量statins增加最多，整體降脂治療藥物及不含pitavastatin之statins亦會增加新生糖尿病，但個別的次群組分析皆未有顯著差異。

Objectives. Trials on the risk of incident diabetes associated with statin therapy have reported conflicting findings. In this meta-analysis, we investigated the relationship between the use of statins, and other commonly used lipid-lowering therapy(LLT) drugs and the risk of new-onset diabetes(NOD). Methods. PubMed in EndNote X8.2 was searched for randomized controlled trials of statins and other lipid-lowering agents published until March 2018. We used the I^2 statistic to measure heterogeneity between trials and calculated the risk estimates for NOD with random-effect meta-analysis. The odds ratio(OR) with 95% CI were calculated with RevMan 5.3 software and the forest plots were drawn with MS-Excel 2016. Results. Ten studies, including eight articles and data from two websites, were included in the meta-analysis. The results showed that intensive-dose statins increased risk of NOD by 33%(OR=1.33, 95% CI: 1.15-1.54), and the overall LLT drugs increased risk of NOD by 9%(OR=1.09, 95% CI: 1.03-1.15). After excluding intensive-dose statins, ezetimibe, and PCSK9i, we did not find the statins to increase NOD risk(OR=1.07, 95% CI: 0.99-1.15). Yet after excluding pitavastatin, the risk of NOD of statins increased by 8%(OR=1.08, 1.003-1.15). Ezetimibe study revealed no increased risk of NOD(OR=1.04, 95% CI: 0.94-1.16). In the FOURIER, evolocumab showed OR=1.05(95% CI: 0.94-1.18) and alirocumab showed OR=0.92(95% CI: 0.42-2.01). Subgroup analysis of the two PCSK9i drugs(OR=1.05, 95% CI: 0.94-1.16) showed no increased risk of NOD. Conclusion. Different types and doses of LLT agents have different effects on risk of NOD. While intensive-dose statins increased risk of NOD the most, and all statins excluding pitavastatin and overall LLT also increased NOD, but individual subgroup analysis of all LLT agents did not reach statistical significance.

1. (1994).Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet,344,1383-1389.
2. (2013).HPS2-THRIVE randomized placebo-controlled trial in 25673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.Eur Heart J,34,1279-1291.
3. Baigent, C,Blackwell, L,Emberson, J(2010).Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet,376,1670-1681.
4. Barkas, F,Elisaf, M,Liberopoulos, E,Klouras, E,Liamis, G,Rizos, EC(2016).Statin therapy with or without ezetimibe and the progression to diabetes.J Clin Lipidol,10,306-313.
5. Barter, PJ,Caulfield, M,Eriksson, M(2007).Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med,357,2109-2122.
6. Blazing, MA,Giugliano, RP,Cannon, CP(2014).Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.Am Heart J,168,205-12e1.
7. Cannon, CP,Braunwald, E,McCabe, CH(2004).Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,350,1495-1504.
8. Ginsberg, HN,Elam, MB,Lovato, LC(2010).Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med,362,1563-1574.
9. Giugliano, RP,Wiviott, SD,Blazing, MA(2017).Long-term safety and efficacy of achieving very low levels of lowdensity lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial.JAMA Cardiol,2,547-555.
10. Henriksbo, BD,Schertzer, JD(2015).Is immunity a mechanism contributing to statin-induced diabetes?.Adipocyte,4,232-238.
11. Huang, CH,Huang, YY,Hsu, BR(2016).Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes.J Diabetes Investig,7,769-776.
12. Jahangir, E,Fazio, S,Sampson, UK(2013).Incident diabetes and statins: the blemish of an undisputed heavy weight champion?.Br J Clin Pharmacol,75,955-958.
13. Karatasakis, A,Danek, BA,Karacsonyi, J(2017).Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.J Am Heart Assoc,6,1-13.
14. Kurogi, K,Sugiyama, S,Sakamoto, K(2013).Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.J Cardiol,62,87-94.
15. LaRosa, JC,Grundy, SM,Waters, DD(2005).Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,352,1425-1435.
16. McMurray, JJ,Kjekshus, J,Gullestad, L(2009).Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.Circulation,120,2188-2196.
17. Navarese, EP,Buffon, A,Andreotti, F(2013).Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.Am J Cardiol,111,1123-1130.
18. Nordestgaard, BG,Chapman, MJ,Humphries, SE(2013).Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.Eur Heart J,34,3478-3490a.
19. Preiss, D,Seshasai, SR,Welsh, P(2011).Risk of incident diabetes with intensive-dose compared with moderatedose statin therapy: a meta-analysis.JAMA,305,2556-2564.
20. Rahal, AJ,ElMallah, AI,Poushuju, RJ,Itani, R(2016).Do statins really cause diabetes?: A meta-analysis of major randomized controlled clinical trials.Saudi Med J,37,1051.
21. Rajpathak, SN,Kumbhani, DJ,Crandall, J,Barzilai, N,Alderman, M,Ridker, PM(2009).Statin therapy and risk of developing type 2 diabetes: a meta-analysis.Diabetes Care,32,1924-1929.
22. Ridker, PM(2009).The JUPITER trial: results, controversies, and implications for prevention.Circ Cardiovasc Qual Outcomes,2,279-285.
23. Robinson, JG,Farnier, M,Krempf, M(2015).Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med,372,1489-1499.
24. Rutti, S,Ehses, JA,Sibler, RA(2009).Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells.Endocrinology,150,4521-4530.
25. Sabatine, MS,Giugliano, RP,Keech, AC(2017).FOURIER Steering Committee and Investigators Evolocumab and clinical outcomes in patients with cardiovascular disease.N Engl J Med,376,1713-1722.
26. Sattar, N,Preiss, D,Murray, HM(2010).Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.Lancet,375,735-742.
27. Stone, NJ,Robinson, JG,Lichtenstein, AH(2014).2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,63,2889-2934.
28. Sugiyama, S,Fukushima, H,Kugiyama, K(2007).Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.Atherosclerosis,194,e43-e51.
29. Takagi, T,Matsuda, M,Abe, M(2008).Effect of pravastatin on the development of diabetes and adiponectin production.Atherosclerosis,196,114-121.
30. Takaguri, A,Satoh, K,Itagaki, M,Tokumitsu, Y,Ichihara, K(2008).Effects of Atorvastatin and Pravastatin on Signal Transduction Related to Glucose Uptake in 3T3L1 Adipocytes.J Pharmacol Sci,107,80-89.
31. Vallejo-Vaz, AJ,Kondapally Seshasai, SR,Kurogi, K(2015).Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes.Atherosclerosis,241,409-418.
32. Waters, DD,Ho, JE,DeMicco, DA(2011).Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.J Am Coll Cardiol,57,1535-1545.
33. Yamakawa, T,Takano, T,Tanaka, S,Kadonosono, K,Terauchi, Y(2008).Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.J Atheroscler Thromb,15,269-275.
34. Yamazaki, T,Kishimoto, J,Ito, C(2011).Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (the J-PREDICT study): rationale, study design, and clinical characteristics of 1269 patients.Diabetol Int,2,134-140.
35. Yu, Q,Chen, Y,Xu, CB(2017).Statins and New-Onset Diabetes Mellitus: LDL Receptor May Provide a Key Link.Front Pharmacol,8,372.